Drug Index



Mechanism :

Fludarabine is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia. It acts at DNA polymerase alpha, ribonucleotide reductase and DNA primase, results in the inhibition of DNA synthesis, and destroys the cancer cells.

Indication :

• Chronic lymphocytic leukemia

• Acute leukemia

• Solid tumors

Contraindications :

Hypersensitivity, Concomitant pentostatin: risk of fatal pulmonary toxicity, Severe renal impairment.

Dosing :

Usual Pediatric Dose for Malignant Disease:

Solid tumors: 7 to 9 mg/m² IV bolus followed by 20 to 27 mg/m²/day continuous IV infusion for 5 days.

Usual Pediatric Dose for Leukemia:

Acute leukemia: 10 mg/m² IV once over 15 minutes followed by continuous IV infusion of 30.5 mg/m²/day for 5 days or 10.5 mg/m² IV once over 15 minutes followed by continuous IV infusion of 30.5 mg/m²/day for 2 days followed by cytarabine.

Usual Pediatric Dose for Stem Cell Transplant Conditioning:

Reduced-intensity conditioning regimen prior to allogenic hematopoietic stem cell transplantation: 30 mg/m²/day for 5 days.

Usual Adult Dose for Chronic Lymphocytic Leukemia:

IV: 25 mg/m² IV once over 30 minutes for 5 days every 28 days. Following a maximal tumor response, 3 additional cycles are recommended.

Oral: 40 mg/m² once daily for 5 days every 28 days.

Usual Adult Dose for non-Hodgkin’s Lymphoma:

25 mg/m²/day for 5 days every 28 days.

Adverse Effect :

Serious Reactions: Neurotoxicity, myelosuppression, pancytopenia, autoimmune hemolytic anemia, tumor lysis syndrome, pulmonary toxicity, pneumonia, opportunistic infection, hypersensitivity reactions, stomatitis, GI bleeding, hemorrhagic cystitis.

Common Reactions: Neutropenia, thrombocytopenia, anemia, fever, rigors, infection,

nausea/vomiting, malaise, fatigue, anorexia, weakness, dyspnea, cough, diaphoresis,

edema, rash.

Interaction :

Dipyridamole: May decrease the effect of fludarabine.
Pentostatin: Unacceptable pulmonary toxicity.
Trastuzumab: May increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
30-7050–75% of normal dose
10-3050–75% of normal dose. Use with care
<1050% of normal dose. Use with care

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in GFR<10 mL/min
HDUnknown dialysability. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–30 mL/min

Hepatic Dose :

No dosage adjustment is recommended.
06/24/2020 05:58:37 Fludarabine
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0